ReviewAntioxidants (Basel, Switzerland)2026
From Dysbiosis to Inflammation: Gut Microbiota and Oxidative Stress in Atopic Dermatitis.
Review in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lipoic acid synthase modulates psoriasis-like keratinocyte dysfunction in association with oxidative stress, ferroptosis-associated remodeling, and STAT3/NF-κB activation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is a chronic inflammatory dermatosis with a complex etiopathogenesis that, despite extensive research, remains incompletely understood. The disorder affects a substantial proportion of the global population and is associated with a significant clinical burden. In recent years, increasing attention has been directed toward the gut microbiota as a potential modulator of the course of inflammatory diseases, including AD. The aim of this review is to critically examine current evidence regarding the association between gut dysbiosis and the exacerbation of inflammatory processes observed in AD. Available studies suggest that alterations in gut microbiota composition may lead to dysregulation of the gut-skin axis, increased intestinal barrier permeability, and activation of pro-inflammatory mechanisms, thereby contributing to the amplification of AD symptoms. Overall, the analyzed findings suggest that the gut microbiota represents a significant yet underexplored component of AD pathogenesis, and that its modulation may define a novel direction for future therapeutic strategies. Elucidating the mechanisms underlying the gut-skin axis may not only inform the development of preventive approaches targeting gut microbiota regulation but also support a broader view of AD as a systemic disorder in which redox imbalance is critically involved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.